Key features and details
- PerCP/Cy5.5® Rat monoclonal [Avas12a1] to VEGF Receptor 2
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Conjugation: PerCP/Cy5.5®. Ex: 482nm, Em: 690nm
- Isotype: IgG2a
Product namePerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1]
See all VEGF Receptor 2 primary antibodies
DescriptionPerCP/Cy5.5® Rat monoclonal [Avas12a1] to VEGF Receptor 2
ConjugationPerCP/Cy5.5®. Ex: 482nm, Em: 690nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Mouse
The details of the immunogen for this antibody are not available.
- Flow cyt: bEnd-3 cells.
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.16% Sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Concentration information loading...
Purification notesPurified from tissue culture supernatant. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.
Light chain typekappa
Our Abpromise guarantee covers the use of ab253080 in the following tested applications.
|Flow Cyt||Use at an assay dependent concentration.
Use at 0.5 μg per reaction.
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 126.96.36.199 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab253080 has not yet been referenced specifically in any publications.